A phase 1 dose-escalation study of protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas

 Gerald S. Falchook, Jon Glass, Varun Monga, Pierre Giglio, David Mauro, John ViscusiPeggy Scherle, Neha Bhagwat, William Sun, Rachel Chiaverelli, Eric Mintah, Lydia Clements, Tanner M. Johanns, Meredith McKean. AACR-NCI-EORTC Annual Meeting 2021; October 7-10, 2021.